Key result
Elevated admission glucose is not linked to 30-day mortality in elderly hospitalized HF patients.
Why the study?
The association between elevated admission glucose and adverse outcomes in patients hospitalized with heart failure has not been well established.
Does elevated admission glucose increase mortality in elderly patients hospitalized with heart failure?
Cohort (n=50,532)
Yes
Does elevated admission glucose increase mortality in elderly patients hospitalized with heart failure?
Hazard Ratio: 1 (95% CI 0.87–1.15)
p-value: p=0.53
In elderly patients hospitalized with heart failure, elevated admission glucose is not significantly associated with increased 30-day or 1-year mortality, challenging the extension of strict glucose control targets to this population.
Admission glucose was not associated with 30-day mortality in elderly HF patients; leaves open whether glucose control improves outcomes.
BACKGROUND: Although some professional societies recommend target-driven glucose control for all hospitalized patients, the association between elevated glucose and adverse outcomes has not been well established in patients hospitalized with heart failure. METHODS AND RESULTS: We evaluated a nationally representative cohort of 50,532 elderly patients hospitalized with heart failure in the United States between April 1998 and June 2001. The association between admission glucose and all-cause mortality at 30 days and 1 year was analyzed with multivariable Cox regression models, both in the entire cohort and in patients with and without diabetes mellitus. After multivariable adjustment, no significant relationship was found between glucose and 30-day mortality (for glucose groups of >110 to 140, >140 to 170, >170 to 200, and >200 mg/dL; hazard ratios for 30-day mortality were 1.09 (95% confidence interval, 0.98 to 1.22), 1.27 (95% confidence interval, 1.11 to 1.45), 1.16 (95% confidence interval, 0.98 to 1.37), and 1.00 (95% confidence interval, 0.87 to 1.15), respectively, versus glucose < or =110 mg/dL; P for linear trend=0.53). Results were similar for 1-year mortality and did not differ between patients with and without known diabetes mellitus (for diabetesxglucose interaction, P=0.11 and 0.55 for 30-day and 1-year mortality, respectively). CONCLUSIONS: We found no significant association between admission glucose levels and mortality in a large cohort of patients hospitalized with heart failure. Our findings suggest that the relationship between hyperglycemia and adverse outcomes seen in acute myocardial infarction cannot be automatically extended to patients hospitalized with other cardiovascular conditions.
No takes yet. Share an insight, caveat, or question.
Kosiborod et al. (2009) conducted a cohort in Heart failure (n=50,532). Elevated admission glucose vs. Admission glucose ≤110 mg/dL was evaluated on All-cause mortality at 30 days (HR 1.00, 95% CI 0.87-1.15, p=0.53). Elevated admission glucose was not significantly associated with 30-day mortality in elderly patients hospitalized with heart failure (HR 1.00; 95% CI 0.87-1.15 for glucose >200 vs ≤110 mg/dL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: